Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05285839
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Last updated on ClinicalTrials.gov
- March 15, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 1
- Eczema Treatment Center of New Jersey · East Windsor, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.